ID

39567

Description

Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection; ODM derived from: https://clinicaltrials.gov/show/NCT02097004

Link

https://clinicaltrials.gov/show/NCT02097004

Keywords

  1. 1/29/20 1/29/20 -
  2. 9/20/21 9/20/21 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

January 29, 2020

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Hepatitis B, Chronic NCT02097004

Eligibility Hepatitis B, Chronic NCT02097004

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. age between 20 and 75 year-old
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
2. hbsag-positive for > 6 months apart (medical history can be alternative)
Description

Hepatitis B surface antigen positive Duration

Data type

boolean

Alias
UMLS CUI [1,1]
C0149709
UMLS CUI [1,2]
C0449238
3. currently being treated with entecavir 0.5 mg/day for more than 18 months
Description

Entecavir Dose U/day

Data type

boolean

Alias
UMLS CUI [1,1]
C0971023
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0456683
4. undetectable hbv dna in serum (<20iu/ml) and hbeag-negative or positive for > 1year
Description

HBV DNA Undetectable | Hepatitis B e Antigens Negative Duration | Hepatitis B e antigen positive Duration

Data type

boolean

Alias
UMLS CUI [1,1]
C3641250
UMLS CUI [1,2]
C3827727
UMLS CUI [2,1]
C0019167
UMLS CUI [2,2]
C1513916
UMLS CUI [2,3]
C0449238
UMLS CUI [3,1]
C0392390
UMLS CUI [3,2]
C0449238
5. hbsag titer < 3,000 iu/ml
Description

Hepatitis B Surface Antigens Titer

Data type

boolean

Alias
UMLS CUI [1,1]
C0019168
UMLS CUI [1,2]
C0475208
6. alt<300 iu/l
Description

Alanine aminotransferase measurement

Data type

boolean

Alias
UMLS CUI [1]
C0201836
7. signed written informed consent after being instructed about the objective and procedure of the clinical study
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. patients with decompensated liver cirrhosis, any one of the following ① serum bilirubin > 3 mg/dl
Description

Decompensated cirrhosis of liver | Serum total bilirubin measurement

Data type

boolean

Alias
UMLS CUI [1]
C1619727
UMLS CUI [2]
C1278039
② prothrombin time > 6 seconds prolonged or inr >2.3
Description

Prothrombin time increased | International Normalized Ratio

Data type

boolean

Alias
UMLS CUI [1]
C0151872
UMLS CUI [2]
C0525032
③ serum albumin < 2.8 g/dl
Description

Serum albumin measurement

Data type

boolean

Alias
UMLS CUI [1]
C0523465
④ history of ascites, variceal hemorrhage, or hepatic encephalopathy
Description

Ascites | Bleeding varices | Hepatic Encephalopathy

Data type

boolean

Alias
UMLS CUI [1]
C0003962
UMLS CUI [2]
C0333106
UMLS CUI [3]
C0019151
⑤ child-pugh score ≥7 (child-pugh class b or c)
Description

Child-Pugh-Turcotte score | Child-Pugh Classification

Data type

boolean

Alias
UMLS CUI [1]
C3854424
UMLS CUI [2]
C2347612
2. patients who have evidence of renal insufficiency defined as serum creatinine>1.5 mg/dl
Description

Renal Insufficiency | Creatinine measurement, serum

Data type

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C0201976
3. patients with psychological problem including depression
Description

Mental problem | Depressive disorder

Data type

boolean

Alias
UMLS CUI [1]
C0848067
UMLS CUI [2]
C0011581
4. patients who have previous/current significant co-morbidities including congestive heart failure, chronic kidney disease, hematologic disease and malignancy including hepatocellular carcinoma(patients with malignancy cured 5 years before screening can be enrolled)
Description

Comorbidity Significant | Congestive heart failure | Chronic Kidney Disease | Hematological Disease | Malignant Neoplasms | Liver carcinoma | Exception Malignant Neoplasm Cured

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0750502
UMLS CUI [2]
C0018802
UMLS CUI [3]
C1561643
UMLS CUI [4]
C0018939
UMLS CUI [5]
C0006826
UMLS CUI [6]
C2239176
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C0006826
UMLS CUI [7,3]
C1880198
5. patients with seropositivity for anti-hcv, anti-hdv or anti-hiv
Description

Hepatitis C Antibodies Seropositive | Hepatitis D antibody Seropositive | HIV Antibodies Seropositive

Data type

boolean

Alias
UMLS CUI [1,1]
C0166049
UMLS CUI [1,2]
C0521143
UMLS CUI [2,1]
C0312635
UMLS CUI [2,2]
C0521143
UMLS CUI [3,1]
C0019683
UMLS CUI [3,2]
C0521143
6. patients who have excessive alcohol consumption (> 30 g/day)
Description

Alcohol intake above recommended sensible limits | Alcohol consumption U/day

Data type

boolean

Alias
UMLS CUI [1]
C0560219
UMLS CUI [2,1]
C0001948
UMLS CUI [2,2]
C0456683
7. patients who have evidence of autoimmune hepatitis, hemochromatosis or wilson's disease
Description

Hepatitis, Autoimmune | Hemochromatosis | Wilson's Disease

Data type

boolean

Alias
UMLS CUI [1]
C0241910
UMLS CUI [2]
C0018995
UMLS CUI [3]
C0019202
8. pregnant or breast feeding females or plan for pregnancy or no contraception
Description

Pregnancy | Breast Feeding | Pregnancy, Planned | Gender Contraceptive methods Absent

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0032992
UMLS CUI [4,1]
C0079399
UMLS CUI [4,2]
C0700589
UMLS CUI [4,3]
C0332197
9. patients with disease may deteriorate with interferon therapy(eg, autoimmune thyroiditis)
Description

Disease Deterioration | Etiology Interferon therapy | Autoimmune thyroiditis

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0868945
UMLS CUI [2,1]
C0015127
UMLS CUI [2,2]
C0279030
UMLS CUI [3]
C0920350
10. patients who have an psoriasis
Description

Psoriasis

Data type

boolean

Alias
UMLS CUI [1]
C0033860
11. patients who have history of antiviral-resistant hbv after previous treatment with oral antiviral agents
Description

Hepatitis B Virus Resistant to Antiviral Therapy | Status post Antiviral Therapy Oral

Data type

boolean

Alias
UMLS CUI [1,1]
C0019169
UMLS CUI [1,2]
C0332325
UMLS CUI [1,3]
C0280274
UMLS CUI [2,1]
C0231290
UMLS CUI [2,2]
C0280274
UMLS CUI [2,3]
C1527415
12. previous diagnosis with immunodeficiency or concomitant treatment of immune suppressive agent or previous organ transplantation recipients
Description

Immunodeficiency | Immunosuppressive Agents | Organ Transplantation Recipient

Data type

boolean

Alias
UMLS CUI [1]
C0021051
UMLS CUI [2]
C0021081
UMLS CUI [3,1]
C0029216
UMLS CUI [3,2]
C1709854
13. patients who have a history of hypersensitivity to study drug
Description

Hypersensitivity Investigational New Drugs

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
14. uncontrollable seizure, convulsion and/or central nervous system disorders
Description

Seizure Uncontrolled | Convulsions Uncontrolled | CNS disorder Uncontrolled

Data type

boolean

Alias
UMLS CUI [1,1]
C0036572
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C4048158
UMLS CUI [2,2]
C0205318
UMLS CUI [3,1]
C0007682
UMLS CUI [3,2]
C0205318
15. patients with severe bone marrow disorder or with history of hypersensitivity to biologic agent such as vaccine.
Description

Bone Marrow Disease Severe | Hypersensitivity Biological agents | Vaccines allergy

Data type

boolean

Alias
UMLS CUI [1,1]
C0005956
UMLS CUI [1,2]
C0205082
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0005515
UMLS CUI [3]
C0571550
16. neutrophil count < 1,500/mm3 or platelet count < 75,000/mm3 or hemoglobin < 10 g/dl
Description

Neutrophil count | Platelet Count measurement | Hemoglobin measurement

Data type

boolean

Alias
UMLS CUI [1]
C0200633
UMLS CUI [2]
C0032181
UMLS CUI [3]
C0518015
17. patients with pulmonary disease (in case of history of pulmonary disease with complete recovery, enrollment is on investigator's discretion)
Description

Lung disease

Data type

boolean

Alias
UMLS CUI [1]
C0024115
18. patients who have a fever ≥ 38 °c at the baseline
Description

Fever

Data type

boolean

Alias
UMLS CUI [1]
C0015967
19. patients who have a risk of febrile response or systemic reaction
Description

At risk Reaction febrile | At risk Systemic Reaction

Data type

boolean

Alias
UMLS CUI [1,1]
C1444641
UMLS CUI [1,2]
C0235723
UMLS CUI [2,1]
C1444641
UMLS CUI [2,2]
C1710276
20. patients who the investigator deems inappropriate to participate in this study
Description

Study Subject Participation Status Inappropriate

Data type

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C1548788

Similar models

Eligibility Hepatitis B, Chronic NCT02097004

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
1. age between 20 and 75 year-old
boolean
C0001779 (UMLS CUI [1])
Hepatitis B surface antigen positive Duration
Item
2. hbsag-positive for > 6 months apart (medical history can be alternative)
boolean
C0149709 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
Entecavir Dose U/day
Item
3. currently being treated with entecavir 0.5 mg/day for more than 18 months
boolean
C0971023 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0456683 (UMLS CUI [1,3])
HBV DNA Undetectable | Hepatitis B e Antigens Negative Duration | Hepatitis B e antigen positive Duration
Item
4. undetectable hbv dna in serum (<20iu/ml) and hbeag-negative or positive for > 1year
boolean
C3641250 (UMLS CUI [1,1])
C3827727 (UMLS CUI [1,2])
C0019167 (UMLS CUI [2,1])
C1513916 (UMLS CUI [2,2])
C0449238 (UMLS CUI [2,3])
C0392390 (UMLS CUI [3,1])
C0449238 (UMLS CUI [3,2])
Hepatitis B Surface Antigens Titer
Item
5. hbsag titer < 3,000 iu/ml
boolean
C0019168 (UMLS CUI [1,1])
C0475208 (UMLS CUI [1,2])
Alanine aminotransferase measurement
Item
6. alt<300 iu/l
boolean
C0201836 (UMLS CUI [1])
Informed Consent
Item
7. signed written informed consent after being instructed about the objective and procedure of the clinical study
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Decompensated cirrhosis of liver | Serum total bilirubin measurement
Item
1. patients with decompensated liver cirrhosis, any one of the following ① serum bilirubin > 3 mg/dl
boolean
C1619727 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
Prothrombin time increased | International Normalized Ratio
Item
② prothrombin time > 6 seconds prolonged or inr >2.3
boolean
C0151872 (UMLS CUI [1])
C0525032 (UMLS CUI [2])
Serum albumin measurement
Item
③ serum albumin < 2.8 g/dl
boolean
C0523465 (UMLS CUI [1])
Ascites | Bleeding varices | Hepatic Encephalopathy
Item
④ history of ascites, variceal hemorrhage, or hepatic encephalopathy
boolean
C0003962 (UMLS CUI [1])
C0333106 (UMLS CUI [2])
C0019151 (UMLS CUI [3])
Child-Pugh-Turcotte score | Child-Pugh Classification
Item
⑤ child-pugh score ≥7 (child-pugh class b or c)
boolean
C3854424 (UMLS CUI [1])
C2347612 (UMLS CUI [2])
Renal Insufficiency | Creatinine measurement, serum
Item
2. patients who have evidence of renal insufficiency defined as serum creatinine>1.5 mg/dl
boolean
C1565489 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
Mental problem | Depressive disorder
Item
3. patients with psychological problem including depression
boolean
C0848067 (UMLS CUI [1])
C0011581 (UMLS CUI [2])
Comorbidity Significant | Congestive heart failure | Chronic Kidney Disease | Hematological Disease | Malignant Neoplasms | Liver carcinoma | Exception Malignant Neoplasm Cured
Item
4. patients who have previous/current significant co-morbidities including congestive heart failure, chronic kidney disease, hematologic disease and malignancy including hepatocellular carcinoma(patients with malignancy cured 5 years before screening can be enrolled)
boolean
C0009488 (UMLS CUI [1,1])
C0750502 (UMLS CUI [1,2])
C0018802 (UMLS CUI [2])
C1561643 (UMLS CUI [3])
C0018939 (UMLS CUI [4])
C0006826 (UMLS CUI [5])
C2239176 (UMLS CUI [6])
C1705847 (UMLS CUI [7,1])
C0006826 (UMLS CUI [7,2])
C1880198 (UMLS CUI [7,3])
Hepatitis C Antibodies Seropositive | Hepatitis D antibody Seropositive | HIV Antibodies Seropositive
Item
5. patients with seropositivity for anti-hcv, anti-hdv or anti-hiv
boolean
C0166049 (UMLS CUI [1,1])
C0521143 (UMLS CUI [1,2])
C0312635 (UMLS CUI [2,1])
C0521143 (UMLS CUI [2,2])
C0019683 (UMLS CUI [3,1])
C0521143 (UMLS CUI [3,2])
Alcohol intake above recommended sensible limits | Alcohol consumption U/day
Item
6. patients who have excessive alcohol consumption (> 30 g/day)
boolean
C0560219 (UMLS CUI [1])
C0001948 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
Hepatitis, Autoimmune | Hemochromatosis | Wilson's Disease
Item
7. patients who have evidence of autoimmune hepatitis, hemochromatosis or wilson's disease
boolean
C0241910 (UMLS CUI [1])
C0018995 (UMLS CUI [2])
C0019202 (UMLS CUI [3])
Pregnancy | Breast Feeding | Pregnancy, Planned | Gender Contraceptive methods Absent
Item
8. pregnant or breast feeding females or plan for pregnancy or no contraception
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032992 (UMLS CUI [3])
C0079399 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
Disease Deterioration | Etiology Interferon therapy | Autoimmune thyroiditis
Item
9. patients with disease may deteriorate with interferon therapy(eg, autoimmune thyroiditis)
boolean
C0012634 (UMLS CUI [1,1])
C0868945 (UMLS CUI [1,2])
C0015127 (UMLS CUI [2,1])
C0279030 (UMLS CUI [2,2])
C0920350 (UMLS CUI [3])
Psoriasis
Item
10. patients who have an psoriasis
boolean
C0033860 (UMLS CUI [1])
Hepatitis B Virus Resistant to Antiviral Therapy | Status post Antiviral Therapy Oral
Item
11. patients who have history of antiviral-resistant hbv after previous treatment with oral antiviral agents
boolean
C0019169 (UMLS CUI [1,1])
C0332325 (UMLS CUI [1,2])
C0280274 (UMLS CUI [1,3])
C0231290 (UMLS CUI [2,1])
C0280274 (UMLS CUI [2,2])
C1527415 (UMLS CUI [2,3])
Immunodeficiency | Immunosuppressive Agents | Organ Transplantation Recipient
Item
12. previous diagnosis with immunodeficiency or concomitant treatment of immune suppressive agent or previous organ transplantation recipients
boolean
C0021051 (UMLS CUI [1])
C0021081 (UMLS CUI [2])
C0029216 (UMLS CUI [3,1])
C1709854 (UMLS CUI [3,2])
Hypersensitivity Investigational New Drugs
Item
13. patients who have a history of hypersensitivity to study drug
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
Seizure Uncontrolled | Convulsions Uncontrolled | CNS disorder Uncontrolled
Item
14. uncontrollable seizure, convulsion and/or central nervous system disorders
boolean
C0036572 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C4048158 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0007682 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
Bone Marrow Disease Severe | Hypersensitivity Biological agents | Vaccines allergy
Item
15. patients with severe bone marrow disorder or with history of hypersensitivity to biologic agent such as vaccine.
boolean
C0005956 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0005515 (UMLS CUI [2,2])
C0571550 (UMLS CUI [3])
Neutrophil count | Platelet Count measurement | Hemoglobin measurement
Item
16. neutrophil count < 1,500/mm3 or platelet count < 75,000/mm3 or hemoglobin < 10 g/dl
boolean
C0200633 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0518015 (UMLS CUI [3])
Lung disease
Item
17. patients with pulmonary disease (in case of history of pulmonary disease with complete recovery, enrollment is on investigator's discretion)
boolean
C0024115 (UMLS CUI [1])
Fever
Item
18. patients who have a fever ≥ 38 °c at the baseline
boolean
C0015967 (UMLS CUI [1])
At risk Reaction febrile | At risk Systemic Reaction
Item
19. patients who have a risk of febrile response or systemic reaction
boolean
C1444641 (UMLS CUI [1,1])
C0235723 (UMLS CUI [1,2])
C1444641 (UMLS CUI [2,1])
C1710276 (UMLS CUI [2,2])
Study Subject Participation Status Inappropriate
Item
20. patients who the investigator deems inappropriate to participate in this study
boolean
C2348568 (UMLS CUI [1,1])
C1548788 (UMLS CUI [1,2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial